Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis c virus genotype 1 infection

Clinical Infectious Diseases

Volumn 59, Issue 12, 2014, Pages 1657-1665

  Howe, Anita Y M ^a   Black, Stuart ^a   Curry, Stephanie ^a   Ludmerer, Steven W ^a   Liu, Rong ^a   Barnard, Richard J O ^a   Newhard, William ^a   Hwang, Peggy M T ^a   Nickle, David ^a   Gilbert, Christopher ^a   Caro, Luzelena ^a   Dinubile, Mark J ^a   Mobashery, Niloufar ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

hepatitis C genotype 1; MK 5172; resistance associated variants; treatment naive

Indexed keywords

GRAZOPREVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; INTERFERON; MK-5172; QUINOXALINE DERIVATIVE; RIBAVIRIN;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REPLICON; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CLINICAL TRIAL;

DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS C; HUMANS; INTERFERONS; QUINOXALINES; RIBAVIRIN;

EID: 84924959983     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu696     Document Type: Article

References (32)

1. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767-77.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
3. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
4. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-24.
5. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
6. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
7. Lawitz E, Rodriguez-Torres M, Stoehr A, et al. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. J Hepatol 2013; 59:11-7.
8. Gambarin-Gelwan M, Jacobson IM. Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors. Curr Gastroenterol Rep 2012; 14:47-54.
9. Ribeiro RM, Li H, Wang S, et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 2012; 8:e1002881.
10. Vallet S, Viron F, Henquell C, et al. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCVgenotypes 1-5. Antivir Ther 2011; 16:1093-102.
11. Vicenti I, Rosi A, Saladini F, et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 2012; 67:984-7.
12. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87:1544-53.
13. Cento V, Mirabelli C, Salpini R, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 2012; 7:e39652.
14. Welsch C, Zeuzem S. Clinical relevance of HCV antiviral drug resistance. Curr Opin Virol 2012; 2:651-5.
15. Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56:4161-7.
16. Manns MP, Vierling JM, Bacon BR, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014; 147:366-76.
17. Koletzki D, Pattery T, Fevery B, Vanhooren L, Stuyver LJ. Amplification and sequencing of the hepatitis C virus NS3/4aprotease and the NS5b polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b. Antiviral methods and protocols. Methods Mol Biol 2013; 1030:137-49.
18. Barnard RJ, McHale CM, Newhard W, et al. Emergence of resistanceassociated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis. Virology 2013; 443: 278-84.
19. Barnard RJ, Howe JA, Ogert RA, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 2013; 444:329-36.
20. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatmentemergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57:221-9.
21. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58:1918.
22. Jacobson I, Dore G, Foster G, et al. Simeprevir (TMC435) with peginterferon/ ribavirin for chronic HCV genotype 1 infection in treatmentnaive patients; results from QUEST-1, a phase III trial. In: Digestive Disease Week, Orlando, Florida, 18-21 May 2013. Poster 1674582. Available at: http://help.infotrieve.com/jsa/070313/Jacobson-DDW% 202013.pdf. Accessed 6 January 2014.
23. Poordad FF, Manns M, Marcellin P, et al. Simeprevir with peginterferon-a2a or-a2b and ribavirin in treatment-naive HCV genotype 1 patients: QUEST-2, a randomized phase III trial. In: Digestive Disease Week, Orlando, Florida, 18-21 May 2013. Available at: http://help. infotrieve.com/jsa/070313/Poordad-oral-DDW%202013.pdf. Accessed 6 January 2014.
24. Lawitz E, Forns X, Zeuzem S, et al. Simeprevir with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. In: Digestive Disease Week, Orlando, Florida, 18-21 May 2013. Available at: http://help.infotrieve.com/jsa/070313/ Lawitz-Oral-Simeprevir%20PROMISE-DDW%202013.pdf. Accessed 7 January 2014.
25. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2013; 49:138-47.
26. HCV Drug Development Advisory Group Phenotype and Sequence Analysis Working Group. Clinically relevant HCV drug resistance mutations, Ann Forum Collab HIV Res 2012; 14:1-10.
27. Graham DJ, Stahlhut M, Flores O, et al. A genotype 2b NS5B polymerase with novel substitutions supports replication of a chimeric HCV 1b:2b replicon containing a genotype 1b NS3-5A background. Antivir Res 2006; 69:24-30.
28. Hara K, Rivera MM, Koh C, et al. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?. J Infect Dis 2014; 209:38-45.
29. Harper S, McCauley JA, Rudd MT, et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 2011; 3:332-6.
30. Romano KP, Ali A, Aydin C, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4a protease inhibitors. PLoS Pathogens 2012; 8:1-15.
31. Akuta N, Suzuki F, Fukushima T, et al. Utility of detection of telaprevirresistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. J Clin Microbiol 2014; 52:193-200.
32. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30ra32.